- Tanomastat
-
- $170.00 / 1mg
-
2026-03-13
- CAS:179545-77-8
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Tanomastat Basic information |
| | Tanomastat Chemical Properties |
| Melting point | 110-110.5°C | | Boiling point | 620.1±55.0 °C(Predicted) | | density | 1.33±0.1 g/cm3(Predicted) | | storage temp. | Sealed in dry,2-8°C | | solubility | Acetone (Slightly), Chloroform (Slightly), Ethyl Acetate (Slightly) | | pka | 4.01±0.23(Predicted) | | form | Solid | | color | White to Off-White | | CAS DataBase Reference | 179545-77-8 |
| | Tanomastat Usage And Synthesis |
| Chemical Properties | White Solid | | Uses | Tanomastat is an orally available, non-peptidic inhibitor of matrix metalloproteinase-2 (MMP-2), MMP-3, and MMP-9 (Kis = 11, 143, and 301 nM, respectively). It is active in various animal models of tumor metastasis and has been used in a phase III clinical trial in pancreatic, SCLC, NSCLC, and ovarian cancer patients. | | Uses | A Matrix Metalloproteinase inhibitor. An angiogenesis inhibitor.Optical Rotation +82° (C 1.5 acetone). | | Uses | A Matrix Metalloproteinase inhibitor. An angiogenesis inhibitor.
Optical Rotation +82(C 1.5 acetone) | | Definition | ChEBI: Tanomastat is an organochlorine compound and a member of biphenyls. | | in vivo | Tanomastat (BAY 12-9566) (100 mg/kg; p.o.; daily for a 7-week period) inhibits local tumor regrowth without causing any toxic effect, and inhibits the number and volume of lung metastases[3]. | Animal Model: | Six- to eight-week-old female BALB/c nude mice (bearing MDA-MB-435 cells)[3] | | Dosage: | 100 mg/kg | | Administration: | p.o.; daily for a 7-week period | | Result: | Inhibited local tumor regrowth by 58% without causing any toxic effect, and inhibited the number and volume of lung metastases by 57 and 88%, respectively. |
| | IC 50 | MMP-2: 11 nM (Ki); MMP-3: 143 nM (Ki); MMP-9: 301 nM (Ki); MMP-13: 1470 nM (Ki) |
| | Tanomastat Preparation Products And Raw materials |
|